Image via discovered:koreaherald.com
Last updated
Samsung Biologics: Restructuring
Samsung Biologics unionized workers voted to leave the Samsung Group United Union and form an independent labor union, following months of work-to-rule campaigns and strikes over pay and working conditions.
Source: discovered:koreaherald.com
The leadership read
Restructuring typically reshapes biotech & pharma leadership bench strength toward transformation and turnaround capability.
Market context: The wider read — a Talent Market Index of 111.4 (Hot), up 5.2 month-on-month — shows Asia signal flow rising (+3.7pts).
Samsung Biologics: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 24 tracked companies; 0.1% of MitchelLake's Asia signal flow.
MitchelLake in this thematic
From the MitchelLake archive
More signals across Biotech & Pharma
Geographic Expansion · Asia
Thermo Fisher Scientific →Thermo Fisher Scientific's Manila Shared Services Centre is scaling rapidly from 100 to ~700 employees by 2026, positioning itself as a high-impact regional hub for Asia-Pacific operations with focus on digital transformation and strategic value creation beyond cost efficiency.
Capital Raising · Asia
Legend Biotech →First Beijing Investment Ltd acquired $43.78 million stake (2.3M shares) in Legend Biotech, a cancer cell therapy developer
Geographic Expansion · Asia
Promomed Group →Promomed Group (Russian pharmaceutical company) is expanding into Vietnam's pharmaceutical market with strategic partnerships. Founder Petr Bely met with Vietnam's Minister of Health to discuss long-term cooperation, technology transfer, and manufacturing operations targeting innovative drugs, biosimilars, and monoclonal antibodies
Partnership · Asia
Bristol Myers Squibb →Bristol Myers Squibb partners with China's Hengrui Pharma on a $15.2 billion deal to advance more than a dozen early-stage drugs
Ma Activity · Asia
Gilead Sciences →Gilead Sciences agreed to acquire Ouro Medicines for up to $2.18 billion, gaining rights to antibody drug licensed from China's Keymed Biosciences
Restructuring · EMEA
Boehringer Ingelheim →Boehringer Ingelheim reducing investments in Germany by $1 billion due to lack of investment predictability in pharmaceutical sector
Intelligence powered by Autonodal ↗